Compromise is reached regarding a COVID-19 vaccine intellectual property waiver for developing countries.
A compromise is reached regarding a COVID-19 vaccine intellectual property waiver for developing countries. According to the compromise, developing countries which have exported less than 10% of the world's COVID-19 vaccine doses in 2021 do not need to seek consent from the owner of the patent before authorising the vaccine. The patent waiver does not apply to other COVID-19-related pharmaceutical products.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
A compromise is reached regarding a COVID-19 vaccine intellectual property waiver for developing countries. According to the compromise, developing countries which have exported less than 10% of the world's COVID-19 vaccine doses in 2021 do not need to seek consent from the owner of the patent before authorising the vaccine. The patent waiver does not apply to other COVID-19-related pharmaceutical products.